Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 041.79 USD -1.19% Market Closed
Market Cap: 984.9B USD

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 366.48 USD. Compared to the current market price of 1 041.79 USD, Eli Lilly and Co is Overvalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
366.48 USD
Overvaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
25
vs Industry
9
Median 3Y
16.1
Median 5Y
13.1
Industry
2.6
Forward
15.3
vs History
49
vs Industry
5
Median 3Y
69.1
Median 5Y
53.2
Industry
21.6
Forward
43.4
vs History
44
vs Industry
5
Median 3Y
81.4
Median 5Y
50.8
Industry
16.5
vs History
55
vs Industry
5
Median 3Y
84.2
Median 5Y
62.8
Industry
22.5
vs History
36
vs Industry
0
Median 3Y
46.5
Median 5Y
35.3
Industry
2.3
vs History
25
vs Industry
8
Median 3Y
16.6
Median 5Y
13.7
Industry
2.9
Forward
15.8
vs History
31
vs Industry
9
Median 3Y
20.7
Median 5Y
16.5
Industry
5.5
vs History
44
vs Industry
7
Median 3Y
47.2
Median 5Y
33.9
Industry
13
Forward
35.5
vs History
49
vs Industry
8
Median 3Y
54.1
Median 5Y
37.4
Industry
16.6
Forward
38.1
vs History
44
vs Industry
5
Median 3Y
84.1
Median 5Y
52.7
Industry
15.8
vs History
7
vs Industry
0
Median 3Y
-190.3
Median 5Y
46.5
Industry
19.1
vs History
28
vs Industry
8
Median 3Y
9.8
Median 5Y
8.1
Industry
1.9

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
985.4B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
506.1B USD 5.5 20.1 16.5 21.4
CH
Roche Holding AG
SIX:ROG
251.4B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 4.8 29.8 107.9 157.9
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 18 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
246.7B USD 3.8 13 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
FR
Sanofi SA
PAR:SAN
101B EUR 1.5 7.3 6.7 6.7
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 21.8
53.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 399.4
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
107.9
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
FR
Sanofi SA
PAR:SAN
6.7
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 710.6
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
157.9
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3
FR
Sanofi SA
PAR:SAN
6.7
15%
0.4